February 3, 2026

Press Release

CMIC HOLDINGS Co., Ltd.

 

Notice Regarding Organizational Restructuring of Group Companies

 

We hereby announce that our subsidiaries, CMIC Pharma Science Co., Ltd. (Head Office: Hokuto City, Yamanashi Prefecture; President & CEO: Takahiro Natsume; hereinafter “CMIC Pharma Science”) and Hamamatsu Pharma Research, Inc. (Head Office: Hamamatsu City, Shizuoka Prefecture; President: Takahiro Natsume; hereinafter “Hamamatsu Pharma Research”) will be integrated through an absorption-type merger, with CMIC Pharma Science as the surviving company and Hamamatsu Pharma Research as the dissolving company.

 

  1. Purpose of the Organizational Restructuring

To maximize business synergies, we will leverage the CMIC brand and the existing streamlined business processes to further reinforce the strengths of Hamamatsu Pharma Research as a foundation.

Through the initiatives outlined below, we aim to enhance our competitiveness in the R&D support business:

  • Establish an organizational structure capable of becoming a global top-tier CRO in the field of pharmacology
  • Strengthen our service delivery framework to meet a wide range of customer needs
  • Develop a system that facilitates extensive technology transfer and acquisition between the two companies, along with the comprehensive collection and shared utilization of scientific information with customers

 

  1. Scheduled Effective Date of the Organizational Restructuring

April 1, 2026

  1. Overview of the Companies Involved in the Merger
(1) Company Name CMIC Pharma Science Co., Ltd. Hamamatsu Pharma Research, Inc.
(2) Head Office Address 10221 Kobuchisawa-cho, Hokuto-shi, Yamanashi 3-7 Shin-Toda 1-chome, Hamana-ku, Hamamatsu-shi, Shizuoka
(3) Representative President & CEO

Takahiro Natsume

 President

Takahiro Natsume
(4) Main Business CRO Business:
– Non-clinical testing

– Bioanalysis

– Quality assurance

 CRO Business:
– Non-clinical efficacy and pharmacology testing
(5) Capital 99 million yen 30 million yen
(6) Number of Employees

(As of Feb. 1, 2026)

 438 37
(7) Major Shareholder CMIC HOLDINGS: 100% CMIC HOLDINGS: 100%

 

■About CMIC Group

CMIC was founded in 1992 as the first contract research organization (CRO) in Japan. To enable pharmaceutical companies to develop better medicine sooner, we expanded our solutions to include contract development and manufacturing (CDMO), site support, and market solutions, supporting global companies to bring highly desired treatments to the Japanese market.

CMIC has also entered into the healthcare arena. Leveraging our vast experience and expertise in the medical industry, we offer solutions using a new ecosystem of healthcare to support the individuals and local governments. We strive to be a Personal Health Value Creator (PHVC) to meet our global customers’ needs in the U.S., Japan, and broader Asia. CMIC Group has over 7,800 employees and 27 sites globally. For more information about CMIC Group and services, please visit our website: https://en.cmicgroup.com/

 

Contact Us for Media Inquiry

CMIC HOLDINGS Co., Ltd.

Corporate Communications

E-mail: pr@cmic.co.jp